Impact of Non-Valvular Non-Coronary Concomitant Procedures on Outcomes of Surgical Aortic Valve Replacement in Intermediate Risk Patients

Fanar Mourad 1, Ali Haddad 2,†, Janine Nowak 1, Mohamed Elbarraki 1, Yacine Elhmidi 3, Marinela Jasarevic 1, Philipp Marx 1, Ender Demircioglu 1, Daniel Wendt 1, Matthias Thielmann 1, Bastian Schmack 1, Arjang Ruhparwar 1 and Sharaf-Eldin Shehada 1,*,†

1 Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center, University Hospital Essen, 45147 Essen, Germany; fanar.mourad@uk-essen.de (F.M.); jainenowak@yahoo.de (J.N.); mo.elbarraki@gmail.com (M.E.); marinela.jasarevic@uk-essen.de (M.J.); Philipp.marx@uk-essen.de (P.M.); ender.demircioglu@uk-essen.de (E.D.); daniel.wendt@uk-essen.de (D.W.); matthias.thielmann@uk-essen.de (M.T.); bastian.schmack@uk-essen.de (B.S.); Arjang.Ruhparwar@uk-essen.de (A.R.)
2 Department of Anaesthesiology and Intensive Care Medicine, University Hospital Essen, 45147 Essen, Germany; ali.haddad@uk-essen.de
3 Department of Cardiac Surgery, Ludwigshafen Heart Centre, 67063 Ludwigshafen, Germany; elhmidy@kiliu.de
* Correspondence: sharaf.shehada@live.com; Tel.: +49-201-723-85556; Fax: +49-201-723-9474905
† S.-E.S. and A.H. are contributed equally and share senior authorship.

Abstract: Introduction: advanced age and concomitant procedures could increase the risk of perioperative complications during surgical aortic valve replacement (SAVR). We aimed to evaluate results of elderly patients undergoing SAVR and evaluate the impact of concomitant non-valvular, non-coronary procedures on the outcomes. Methods: A retrospective single-centre study, evaluating 464 elderly patients (mean age = 75.6 ± 4 years) undergoing either isolated-SAVR (I-SAVR = 211) or combined-SAVR (C-SAVR = 253) between 01/2007 and 12/2017. Combined-SAVR involved non-valvular, non-coronary procedures. Study endpoints are postoperative results concerning the VARC-II criteria, valve dysfunction, long-term freedom from redo-AVR and survival. Results: males were 52.8%. Patients had an intermediate risk profile (mean EuroSCORE-II (%) 5.2 ± 5). Postoperative results reported no significant differences in incidence of re-exploration for bleeding (6.6% vs. 6.7%, p = 1.0), stroke (0.9% vs. 0.4%, p = 0.59), dialysis (6.2% vs. 9.5%, p = 0.23) and pacemaker implantation (3.3% vs. 2.8%, p = 0.79) between I-SAVR and C-SAVR groups. Thirty-day (2.4% vs. 7.1% p = 0.03), one-year (5.7% vs. 13.8%, p = 0.003) and overall mortality (24.6% vs. 37.5%, p = 0.002) were lower in the isolated-SAVR group. Re-AVR was indicated in 1.7% of patients due to endocarditis. Conclusions: SAVR in elderly patients offers good outcomes with increased life quality and rare re-operation for structural valvular deterioration. Mortality rates were significantly higher when SAVR was combined with another “non-valvular, non-coronary” procedure.

Keywords: surgical aortic valve replacement; intermediate risk patients; isolated and combined aortic valve replacement

1. Introduction

Age distribution of cardiac surgery patients in Germany shows an increased shift towards an elderly population. In 2019, the German Heart Surgery Report reported that more than 53% of cardiac procedures were performed in patients older than 70 years during the last ten years [1]. It registered a total of 174,902 cardiac procedures, of these 18.75% (32,810) were aortic valve procedures; most of them (59.2%) were either isolated or combined surgical aortic valve replacement (SAVR) [1]. SAVR can be performed either conventional...
or minimally invasively via partial sternotomy or right lateral mini-thoracotomy [2,3].
Recently, trans-catheter aortic valve implantation (TAVI) has been more frequently adopted
in isolated aortic valve procedure in high-risk patients, then in intermediate risk and now
in low risk patients [4,5]. In Germany, the number of TAVI procedures increased from 2198
in 2009 to 13,279 in 2018, which represents 57.5% of the isolated aortic valve procedures [1].
Different strategies, implantation modifications and different outcomes and complications
have been widely discussed for the TAVI procedures [6–8]. However, combined
non-valvular and non-coronary pathologies, including ascending aorta aneurysm, septum
hypertrophy, small annuli, atrial fibrillation (AF) and patent foramen ovale (PFO), are
factors leading to SAVR procedure. We therefore aimed to evaluate the additional risk of
morbidity and mortality of those combined pathologies and procedures on intermediate
risk patients undergoing SAVR.

2. Patients and Methods

2.1. Study Design and Patients

This is a retrospective single-centre study that evaluates 464 consecutive elderly
(≥70 years) patients undergoing SAVR between 01/2007 and 12/2017. They undergo either
isolated or combined SAVR with non-valvular non-coronary procedures: Ascending aorta
repair/replacement, aortic root enlargement, sub-valvular myectomy or decalcification,
PFO or left atrial appendage closure, ablation and intra cardiac tumour resection. Patients
with combined SAVR with composite conduit (i.e., David, Yacoub or Bentall), aortic arch
surgery, mitral or tricuspid valve procedures or coronary artery bypass grafting and redo
procedures were excluded. The study obtained a review board approval according to the
University Hospital Ethics Committee (Ref# 18-8421-BO).

2.2. Data Collection and Follow-Up

Patients’ preoperative, operative and postoperative data were recorded in our in-
stitutional database. A retrospective data extraction and evaluation was performed. A
follow-up was performed by reviewing medical records and communication with civil office
as well as an active personal or phone-call interview using a standardized questionnaire
that was established in reference to the EuroQol-questionnaire to evaluate patients’ general
and clinical status. The follow-up was continued until an endpoint of death or completion
of the study through September 2020. The follow-up for survival was 100% completed;
however, 23 survivals did not fill out the questionnaire, resulting in 95% completion for the
clinical follow-up.

2.3. Study Endpoints

Primary endpoints were postoperative morbidities in reference to the Valve Academic
Research Consortium II initiative (VARC II) criteria, which included 30-day mortality, inci-
dence of stroke, myocardial infarction, re-exploring for bleeding, acute kidney insufficiency,
new haemodialysis, pacemaker implantation and new onset of arterial fibrillation. Sec-
ondary endpoints were freedom of re-aortic valve replacement (AVR) or valve dysfunction
and overall long-term survival.

2.4. Statistics

A descriptive statistical analysis was performed using the SPSS-software (version
22.0. IBM Corp., Armonk, NY, USA). Continuous data were expressed as mean ± stand-
ard deviation (SD) or median with interquartile ranges (IQRs) (25–75th percentiles) and
compared between groups using the unpaired Student’s t-test or Mann–Whitney U test
when appropriate. Categorical data were expressed as frequencies and percentages and
compared between groups using Chi-Square ($\chi^2$) test or Fisher’s exact test. Reported
p-values are two-sided and a value of $p < 0.05$ was considered statistically significant. Ad-
ditionally, Kaplan–Meier curves were generated using the R software to estimate freedom
from cardiac or all-cause mortality in both groups; log-rank test was used to evaluate differences between both groups.

3. Results

3.1. Patient Population

A total of 464 consecutive elderly patients undergo either isolated-SAVR (I-SAVR) in 211 (45.5%) patients or combined-SAVR (C-SAVR) with non-valvular, non-coronary procedure in 253 (54.5%) patients. Detailed baseline characteristics are summarized in Table 1. Mean age was 75.6 ± 4 years and the cohort included more males (52.8%), where 6% of the patients presented for an urgent/salvage procedure. Risk scores in both groups reported intermediate risk with significant higher risk scores in the C-SAVR group: Logistic EuroSCORE I (15.2 ± 12.3 vs. 9.6 ± 7, \( p < 0.0001 \)), EuroSCORE II (6.7 ± 6.2 vs. 2.9 ± 2.4, \( p < 0.0001 \)). Patients in the I-SAVR presented with advanced NYHA classifications NYHA III-IV (60.7% vs. 43.5%, \( p < 0.0001 \)) compared to C-SAVR patients. Table 2 contains preoperative echocardiographic data. Most of the patients presented with either aortic valve stenosis (50.4%) or concomitant stenosis with regurgitation (42.5%). Morphologically 80.4% of the patients have tricuspid aortic valve with a mean orifice area of 0.93 ± 0.3 cm² and a mean gradient of 50.6 ± 23.3 mmHg. Impaired left ventricular function was reported in 94 (20.2%) patients.

| Table 1. Baseline characteristics. |
|-----------------------------------|
| **Variable**                      | **Total** | **Isolated–SAVR** | **Combined–SAVR** | **p-Value** |
| Demographics                      |           |                  |                  |            |
| Age, years                        | 75.6 ± 4  | 75.2 ± 3.6       | 75.9 ± 4.3       | 0.06       |
| Gender, male                      | 245 (52.8)| 123 (58.3)       | 122 (48.2)       | 0.03       |
| BMI *, kg/m²                       | 27.8 ± 5.1| 28.2 ± 4.8       | 27.5 ± 5.3       | 0.14       |
| Risk factors & comorbidities      |           |                  |                  |            |
| Peripheral vascular disease       | 34 (7.3)  | 17 (8.1)         | 17 (6.7)         | 0.59       |
| Hypertension                      | 397 (85.6)| 176 (83.4)       | 221 (87.3)       | 0.24       |
| COPD *                            | 89 (19.2) | 48 (22.7)        | 41 (16.2)        | 0.08       |
| Diabetes mellitus                 | 115 (24.8)| 53 (25.1)        | 62 (24.3)        | 0.91       |
| Pulmonary hypertension            | 78 (16.8) | 39 (18.5)        | 39 (15.4)        | 0.39       |
| Hyperlipidaemia                   | 229 (49.3)| 94 (44.5)        | 135 (53.4)       | 0.06       |
| Prior dialysis                    | 7 (1.5)   | 4 (1.9)          | 3 (1.2)          | 0.71       |
| Prior myocardial infarction        | 18 (3.9)  | 7 (3.3)          | 11 (4.3)         | 0.64       |
| Prior cerebrovascular accident    | 36 (7.7)  | 11 (5.2)         | 25 (9.9)         | 0.08       |
| Prior pacemaker implantation      | 25 (5.4)  | 10 (4.7)         | 15 (5.9)         | 0.68       |
| NYHA * III-IV                     | 238 (51.3)| 128 (60.7)       | 110 (43.5)       | <0.0001    |
| Urgent/Emergent indication        | 28 (6.0)  | 15 (7.1)         | 13 (5.1)         | 0.31       |
| Risk-scores                       |           |                  |                  |            |
| Logistic EuroSCORE I              | 12.6 ± 10.6| 9.6 ± 7          | 15.2 ± 12.3      | <0.0001    |
| EuroSCORE II                      | 5.2 ± 5   | 2.9 ± 2.4        | 6.7 ± 6.2        | <0.0001    |
| STS-PROM                           | 2.3 ± 1.7 | 2.3 ± 1.6        | 2.4 ± 1.8        | 0.411      |

Data are presented as mean ± SD or number (%). * BMI = Body mass index; * COPD = Chronic obstructive pulmonary disease; * NYHA = New York Heart Association.

3.2. Operative Outcomes

Table 3 summarizes the operative outcomes. A minimally invasive procedure via partial sternotomy was performed in 26.5% of patients. Most patients received biological prosthesis (97.6%) with a mean size of 23 ± 2 mm. C-SAVR patients have longer cross clamp time and CPB times (69.9 ± 23.4 vs. 60.7 ± 17.3 min, \( p < 0.0001 \) and 101.9 ± 37.9 vs. 88.9 ± 25.1 min, \( p < 0.0001 \)) than isolated SAVR. The same group required more intraoperative foreign blood transfusion (587.8 ± 493.5 vs. 449.9 ± 435.8 mL, \( p < 0.0001 \)). C-SAVR patients underwent one or more concomitant procedures, which were mainly sub-valvular myectomy and/or decalcification (70%), ascending aorta repair/replacement.
(30%), aortic root enlargement (8.7%), closure of a patent foramen ovale (9.1%), left atrial appendage occlusion or rhythm procedure (13.4%) or resection of an atrial tumour (1.4%).

Table 2. Preoperative echocardiographic data.

| Variable                              | Total n = 464 | Isolated–SAVR n = 211 | Combined–SAVR n = 253 | p-Value |
|----------------------------------------|---------------|------------------------|-----------------------|---------|
| **Aortic valve Pathology**             |               |                        |                       |         |
| Isolated stenosis                      | 234 (50.4)    | 109 (51.7)             | 125 (49.4)            | 0.64    |
| Isolated regurgitation                 | 25 (5.4)      | 6 (2.8)                | 19 (7.5)              | 0.04    |
| Combined stenosis & regurgitation      | 197 (42.5)    | 93 (44.1)              | 104 (41.1)            | 0.57    |
| Aortic valve endocarditis              | 8 (1.7)       | 3 (1.4)                | 5 (2.0)               | 0.73    |
| **Aortic valve morphology**            |               |                        |                       |         |
| Unicuspid                              | 2 (0.4)       | 1 (0.5)                | 1 (0.4)               | 1.0     |
| Bicuspid                               | 89 (19.2)     | 36 (17.1)              | 53 (20.9)             | 0.34    |
| Tricuspid                              | 373 (80.4)    | 174 (82.4)             | 199 (78.7)            | 0.35    |
| **Impaired Left ventricle ejection fraction** |       |                        |                       |         |
| EF < 30%                               | 10 (2.1)      | 4 (1.9)                | 6 (2.4)               | 0.76    |
| EF 30–50%                              | 84 (18.1)     | 43 (20.4)              | 41 (16.2)             | 0.28    |
| Aortic valve orifice area (cm²)        | 0.93 ± 0.3    | 0.91 ± 0.3             | 0.96 ± 0.3            | 0.04    |
| Mean gradient, mmHg                    | 50.6 ± 23.3   | 48.5 ± 21.2            | 54 ± 26.1             | 0.19    |

Data are presented as Mean ± SD or number (%). EF = ejection fraction.

Table 3. Operative outcomes.

| Variable                              | Total n = 464 | Isolated–SAVR n = 211 | Combined–SAVR n = 253 | p-Value |
|----------------------------------------|---------------|------------------------|-----------------------|---------|
| Biological prosthesis                  | 453 (97.6)    | 209 (99.1)             | 244 (96.4)            | 0.07    |
| Prosthesis size, mm                    | 23 ± 2        | 23 ± 2                 | 23 ± 2                | 0.88    |
| Aortic cross clamp time, min           | 66 ± 21       | 61 ± 17                | 70 ± 23               | <0.0001 |
| Intraoperative Blood transfusion, ml   | 525 ± 490     | 450 ± 436              | 588 ± 494             | <0.0001 |
| **Concomitant Procedures**             |               |                        |                       |         |
| Ascending aorta repair/replacement     | 76            | -                      | 76 (30)               | -       |
| Aortic root enlargement                | 22            | -                      | 22 (8.7)              | -       |
| Sub-valvular                           | 177           | -                      | 177 (70)              | -       |
| * PFO closure                          | 23            | -                      | 23 (9.1)              | -       |
| * LAA occlusion ± Ablation             | 34            | -                      | 34 (13.4)             | -       |
| Atrial tumours resection               | 4             | -                      | 4 (1.6)               | -       |

Data presented as mean ± SD or number (%). * PFO = Patent Foramen Ovale; * LAA = Left atrial appendage.

3.3. Postoperative Outcomes

Postoperative results show no difference between I-SAVR and C-SAVR patients in regard to myocardial infarction (0.5% vs. 0%, p = 0.46), revision for bleeding (6.6% vs. 6.7%, p = 1.0), need for temporary dialysis (6.2% vs. 9.5%, p = 0.23), pacemaker implantation (3.3% vs. 2.8%, p = 0.79) or new onset of atrial fibrillation (33.6% vs. 27.6%, p = 0.19). Combined-SAVR has significantly more 30-day mortality (7.1% vs. 2.4%, p = 0.03) but similar cardiac-related mortality (2.8% vs. 1.9%, p = 0.76) as reported in Table 4.

3.4. Late and Follow-Up Outcomes

Survival follow-up was 100% completed and is reported in Table 4, showing higher incidence of cumulative one-year (13.8% vs. 5.7%, p = 0.003), five-year (13.8% vs. 5.7%, p = 0.003) and overall (37.5% vs. 24.6%, p = 0.002) mortalities in the combined-SAVR group, as also illustrated with Kaplan–Meier curves (Figure 1A,B), and showing significant lower cardiac mortality (log-rank = 0.03), but slightly non-significant all-cause (log-rank = 0.05) mortality in the I-SAVR group. The random survival forest revealed that concomitant SAVR was a significant factor associated with all-cause mortalities (p = 0.002) and cardiac mortalities (p = 0.01). More details can be found in the Supplementary Table S1. Table 5
summarizes clinical outcomes of the survivals: No differences were recorded between both groups regarding incidence of structural prosthesis deterioration, indicating reoperation (1.4% vs. 2%, p = 1.0) or prosthesis dysfunction not indicating re-surgery (3.5% vs. 4.6%, p = 0.88). The indication for re-SAVR was severe destructive endocarditis in all patients. Furthermore, no differences were observed in the incidence of stroke (4.9% vs. 5.9%, p = 0.8), myocardial infarction (1.4% vs. 0%, p = 0.88), or coronary revascularization (1.4% vs. 2.6%, p = 0.69) between both groups, respectively. Most of the survivals were physically independent (73.5%) and presented with NYHA I-II classification (74.8%).

Table 4. Postoperative and survival outcomes.

| Variable | Total n = 464 | Isolated–SAVR n = 211 | Combined–SAVR n = 253 | p-Value |
|----------|--------------|------------------------|------------------------|---------|
| **Early outcomes** | | | | |
| Ventilation time, hours | 10 (7–18) | 10 (6–18) | 10 (7–17) | 0.21 |
| Intensive-care stay, hours | 25 (21–70) | 25 (21–50) | 28 (21–91) | 0.94 |
| Blood transfusion, ml | 600 (0–600) | 300 (0–600) | 600 (0–600) | 0.07 |
| Re-exploration for bleeding | 31 (6.7) | 14 (6.6) | 17 (6.7) | 1.0 |
| Deep wound infection | 2 (0.4) | 2 (0.8) | 0 | 0.21 |
| Low cardiac output syndrome | 14 (3.0) | 4 (1.9) | 10 (3.9) | 0.28 |
| Myocardial infarction | 1 (0.2) | 1 (0.5) | 0 | 0.46 |
| Temporary dialysis | 37 (8.0) | 13 (6.2) | 24 (9.5) | 0.23 |
| Re-Intubation | 25 (5.4) | 12 (5.7) | 13 (5.1) | 0.84 |
| Stroke | 3 (0.6) | 2 (0.9) | 1 (0.4) | 0.59 |
| New onset atrial fibrillation | 141 (30.4) | 71 (33.6) | 70 (27.6) | 0.19 |
| Pacemaker implantation | 14 (3.0) | 7 (3.3) | 7 (2.8) | 0.79 |
| 30-days mortality | 23 (4.9) | 5 (2.4) | 18 (7.1) | 0.03 |
| Cardiac-related mortality | 11 (2.4) | 4 (1.9) | 7 (2.8) | 0.76 |
| **One year mortality** | 47 (10.1) | 12 (5.7) | 35 (13.8) | 0.003 |
| Due to cardiac causes | 16 (3.4) | 5 (2.4) | 11 (4.3) | |
| Due to non-cardiac causes | 18 (3.9) | 4 (1.9) | 14 (5.5) | |
| Due to unknown causes | 13 (2.8) | 3 (1.4) | 10 (3.9) | |
| **Five-year mortality** | 84 (18.1) | 26 (12.3) | 58 (22.9) | 0.007 |
| Due to cardiac causes | 17 (3.7) | 5 (2.4) | 12 (4.7) | |
| Due to non-cardiac causes | 36 (7.8) | 11 (5.2) | 25 (9.9) | |
| Due to unknown causes | 31 (6.7) | 10 (4.7) | 21 (8.3) | |
| **Overall mortality** | 147 (31.7) | 52 (24.6) | 95 (37.5) | 0.002 |
| Due to cardiac causes | 20 (4.3) | 5 (2.4) | 15 (5.9) | |
| Due to non-cardiac causes | 62 (13.4) | 22 (10.4) | 40 (15.8) | |
| Due to unknown causes | 65 (14) | 25 (11.8) | 40 (15.8) | |
| **Lost during follow-up** | 23 (5) | 7 (3.3) | 16 (6.3) | 0.002 |
| Follow-up time, months | 88.8 ± 39.4 | 87.3 ± 36.7 | 89.9 ± 41.4 | 0.21 |

Data presented as number (%) or median with interquartile range.

Table 5. Clinical follow-up outcomes.

| Variable | Total n = 294 | Isolated–SAVR n = 152 | Combined–SAVR n = 142 | p-Value |
|----------|--------------|------------------------|------------------------|---------|
| Social history | | | | |
| Independently patient | 216 (73.5) | 112 (73.7) | 104 (73.2) | 0.54 |
| Need help | 78 (26.5) | 40 (26.3) | 38 (26.7) | 0.54 |
| Survivals * NYHA classification | | | | |
| NYHA I-II | 220 (74.8) | 110 (72.4) | 110 (77.5) | 0.35 |
| NYHA III-IV | 74 (25.2) | 42 (27.6) | 32 (22.5) | 0.35 |
| Stroke | 16 (5.4) | 9 (5.9) | 7 (4.9) | 0.8 |
| Myocardial infarction | 2 (0.7) | 0 | 2 (1.4) | 0.23 |
| * PCI / Stent implantation | 6 (2.0) | 4 (2.6) | 2 (1.4) | 0.69 |
| Pacemaker implantation | 15 (5.1) | 4 (2.6) | 11 (7.7) | 0.06 |
Table 5. Cont.

| Variable                                      | Total $n = 294$ | Isolated–SAVR $n = 152$ | Combined–SAVR $n = 142$ | $p$-Value |
|-----------------------------------------------|-----------------|-------------------------|-------------------------|-----------|
| New temporary haemodialysis                   | 3 (1.0)         | 3 (2.0)                 | 0                       | 0.25      |
| Prosthesis dysfunction requiring * Re-SAVR    |                 |                         |                         |           |
| Severe prosthesis endocarditis                | 5 (1.7)         | 3 (2.0)                 | 2 (1.4)                 | 1.0       |
| Prosthesis dysfunction without * Re-SAVR      | 12 (4.0)        | 7 (4.6)                 | 5 (3.5)                 | 0.88      |
| Prosthesis stenosis                           | 3 (1.0)         | 1 (0.7)                 | 2 (1.4)                 |           |
| Prosthesis insufficiency                      | 6 (2.0)         | 4 (2.6)                 | 2 (1.4)                 |           |
| Prosthesis endocarditis                       | 3 (1.0)         | 2 (1.3)                 | 1 (0.7)                 |           |

Data presented as number (%). * PCI = percutaneous coronary intervention; * Re-SAVR = redo surgical aortic valve replacement; * NYHA = New York Heart Association Classification.

Figure 1. Kaplan–Meier curves showing: (A) Freedom from all-cause mortality in both subgroups. (B) Freedom from cardiac mortality in both subgroups.

4. Discussion

The main findings of this study were: 1. There were no significant differences between the two groups in regard to VARC II criteria except for all-cause early mortality. 2. Patients undergoing SAVR with combined procedures have a two- to threefold higher postoperative mortality than those without.

Different outcomes of SAVR in elderly patients have been reported based on patients’ clinical status, comorbidities, procedural time, as well as concomitant procedures. In this study, 464 consecutive elderly patients (≥70 years) who underwent SAVR were evaluated; a 30-day mortality was reported in 4.9% of patients, significantly lower in the isolated-SAVR group (2.4% vs. 7.1%, $p = 0.03$). To be precise, investigation of the deaths and cardiac mortality was reported in 2.4% of patients. Moreover, most (12/23) of the patients who
died had higher risk scores (log. EuroSCORE 24.3 ± 4.2%); this decreased with time after the increased adoption of TAVI procedure in high-risk patients; similarly, in this study, early mortality decreased to 3.5% (9/255) after 2010. Thus, when looking at patients with lower-risk scores in this cohort, 30-day mortality was reported in only 0.7% (1/149) of patients, which in turn is comparable to the recently published TAVI in low risk-data [4,5]. Early mortality was reported in 2.4% of patients in isolated-SAVR, which was slightly lower than the unadjusted mortality rate of isolated-SAVR in the German annual report, which varies between 2.6% and 2.9% within the last 10 years [1], and the crude 3.1% (95% CI, 2.6–3.7%) mortality rate of SAVR without concomitant-CABG for elderly patients in the united states between 1999 and 2011 [9].

Long-term outcomes after TAVI are still under investigation. Some investigators reported comparable five-year mortality between TAVI and SAVR in intermediate and high-risk patients [10,11]. In the recently published meta-analysis evaluating different randomized trials from Barili et al. survival advantage was observed in patients undergoing TAVI in the first year after the procedure; this however was changed later on, where at 40 months the survival rates would favour SAVR patients; this was attributed to other factors involving perioperative pacemaker implantation, significant perivalvular leaks and durability of the TAVI-prosthesis [12]. In our study, the estimated 10-year survival reaches around 40%, which is similar to early reported data from other investigators [13,14].

The impact of concomitant non-valvular, non-coronary procedures on outcome after SAVR is not widely discussed, such as ascending aorta repair or replacement, aortic root enlargement, sub-valvular myectomy or decalcification, which sometimes reach down to the anterior mitral leaflet. In fact, all these concomitant procedures subsequently increase of intraoperative complications or postoperative bleeding with immense prolonged post-operative course and hence the risk of mortality. Thus, the question is whether there is any benefit to perform such concomitant procedures during SAVR. Such pathologies are not addressed during treatment within TAVI procedures.

Earlier studies addressing this reported that SAVR could have a protective role in the progression of ascending aorta dilatation as well as hypertrophy of the left ventricular septum [15,16]. Others reported no increase in mortality rate after selected concomitant procedures including root enlargement, sub-valvular myectomy and ablation procedures [17–19]. In fact, our study demonstrates significant lower early (2.4% vs. 7.1%, $p = 0.03$) and late mortalities (24.6% vs. 37.5%, $p = 0.002$) in the isolated SAVR group than the combined-SAVR with non-valvular, non-coronary procedure. Of note, most of the patients who died (11 out of 18 for the 30-day and 51 out of 95 for the late mortalities) in the second group underwent concomitant sub-valvular myectomy. In our study, about 45.5% (115/253) of patients in the combined group presented for surgery in advanced status of left ventricular hypertrophy, which has already been reported as a negative predictor of early mortality in SAVR [20]. Additionally, 19% (48/253) of the patients had atrial fibrillation, which also would be associated with a more than two-fold increased risk of cardiac and all-cause mortality after TAVI and considered as an independent predictor of late adverse cardiac and cerebrovascular events after SAVR [21]. Earlier aortic valve intervention for patients with moderate to severe aortic stenosis with increasing left ventricle mass even if they are asymptomatic has been reported to have better early and late survival [22]. Therefore, frequent clinical and echocardiographic examination to identify early and treat aortic stenosis in those patients, besides optimizing therapy for the risk factor, is essential to improve outcomes.

This reflects the importance of the right timing of aortic valve stenosis intervention rather than judging the procedure (SAVR or TAVI) itself. Small aortic annuli is a competitive finding facing both SAVR and TAVI, which might easily result in patient prosthesis mismatch (PPM), resulting in decreased long-term survival and increased rehospitalisation due to heart failure or for re-SAVR [23]. Concomitant aortic root enlargement is considered as an effective method to avoid PPM in small aortic annuli, with no increase in the early mortality, and allows better long-term outcomes [17]. Advanced technology of valve production in the current era provides another opportunity for those patients; it aims to
avoid PPM similar to aortic root enlargement, involving the use of supra annular stented prostheses [24,25] or sutureless prostheses, which have no suturing ring and accordingly increased effective valvular orifice area [26]. These alternatives could facilitate procedure and decreases the rate of root enlargement-associated complications. Of note, transcatheter prostheses could present a significantly better effective orifice area and maybe should be kept in mind as a good alternative in challenging obese patients with small aortic annuli.

Generally, the main purpose of ascending aorta repair or replacement is to prevent acute aortic events (dissection, rupture, pseudo-aneurysm). The guidelines depend in this regard mostly on the diameter of the aorta to identify the indication for surgery; the current ones indicate concomitant aortic repair in patients undergoing aortic valve replacement when the ascending aortic diameter ≥ 45 mm [27]. Several studies showed low expansion rate and acute aortic events and rare or no reoperation on a dilated ascending aorta after isolated SAVR in cases of tricuspid aortic valves within mid- to long-term follow-up [15]. This differs in cases of bicuspid aortic valve (BAV), Yasuda et al. reported further dilation of ascending aorta after isolated SAVR and attributed that to the fragility of the aortic wall rather than the hemodynamic factors [28]; other investigators reported stable diameter of dilated aorta in stenotic BAV patients for at least 10 year after isolated SAVR [29].

Recently, encouraging early and mid-term outcomes have been reported for patients with aneurysmatic ascending aorta undergoing only TAVI [30]. In this study, 30% (76/253) of the combined-group patients underwent ascending aorta repair or replacement, where 30-day, one-year and late mortalities were observed in 3/76 (3.9%), 10/76 (13.2%) and 20/76 (26.3%) of the patients, respectively. Therefore, after considering the guidelines’ recommendations, the indication for concomitant ascending aorta procedure in elderly patients during SAVR could be limited to a few categories, e.g., patients with connective tissue disorders or those with familial aortic aneurysms and in selected BAV phenotypes.

In the current study, redo-AVR was reported in 5 (1.1%) patients due to prosthesis endocarditis and not due to structural valve deterioration (SVD). Interestingly, during clinical and echocardiographic follow-up a few patients had subclinical bio-prosthesis changes without the need for re-AVR, which are presented as a mild increase in the transvalvular gradient in 3/294 (1%), mild aortic insufficiency in 6/294 (2%), as well as prosthesis endocarditis in 3/294 (1%) patients, which were treated conservatively with antibiotics. A possible explanation of this low rate of SVD could be the used prosthesis where Carpentier–Edwards Perimount prosthesis (Edwards Lifesciences, Irvine, CA, USA) and St. Jude Trifecta prosthesis (St. Jude Medical, St. Paul, MN, USA) was implanted in 67.2% (312/464) and in 23.9% (111/464) of patients, respectively. Those prostheses have reported excellent durability and low SVD rates, especially in elderly patients [31,32].

Finally, a long-term clinical follow-up at 88.8 ± 39.4 months shows significant improvement of life quality and absence of symptoms after surgery for those elderly patients. Most patients (73.5% (216/294)) were independent of help and 74.8% (220/294) presented with NYHA I-II, with low incidence rates of late stroke (16/294, 5.4%), myocardial infarction (2/294, 0.7%) and pacemaker implantation (15/294, 5.1%), which is comparable with results after TAVI in low-risk patients [4,5]. This quality of life benefit is in accordance with the early reported data of a large meta-analysis reviewing postoperative health-related quality of life (HRQOL) after SAVR in elderly that suggests evaluating patients for surgery based on their comorbidities rather than their age [33].

5. Conclusions

SAVR in intermediate risk patients was associated with acceptable early and long-term outcome with increased life quality and re-operation for structural prosthesis deterioration was rare. Interestingly, some non-valvular, non-coronary concomitant procedures seem to have a negative impact on results. This could be due to the advanced underlying pathologies and delayed surgical timing. Thus, frequent echocardiographic and clinical observation of those patients and discussing of their findings in heart team to choose
optimal time, treatment strategy and indication of concomitant procedure is mandatory to improve outcomes.

6. Study Limitation

Our study was performed at a single centre with a relatively small cohort; however, it presents long-term outcomes for elderly patients who underwent either isolated or combined non-valvular, non-coronary SAVR, which so far not addressed in the literature. The heterogeneity between both groups in regards to preoperative data could affect results; a matching analysis was not performed due to the small sample size in each group, even though, these data present a part of our daily practice and a kind of real-world outcome. The nature of the study being a retrospective one, and finally the absence of a comparison group undergoing TAVI are limitations of this study.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/jcm10235592/s1, Table S1: Multivariate random survival forest.

Author Contributions: F.M. & S.-E.S.: Concept, design, data analysis, drafting & revision; J.N., M.E. & M.J.: Data collection; A.H. & E.D.: Methodology, investigation & resources; Y.E., P.M., D.W., M.T., B.S. & A.R.: Critical revision & editing. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Hospital Ethics Committee (Ref# 18-8421-BO).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study at the time of admission before surgery allowing a possible date and outcomes publication anonymously.

Conflicts of Interest: All authors declare no conflict of interest.

References
1. Beckmann, A.; Meyer, R.; Lewandowski, J.; Markewitz, A.; Harringer, W. German Heart Surgery Report 2018: The Annual Updated Registry of the German Society for Thoracic and Cardiovascular Surgery. Thorac. Cardiovasc. Surg. 2019, 67, 331–344. [CrossRef]
2. Shehada, S.-E.; Elhmidi, Y.; Mourad, F.; Wendt, D.; El Gabry, M.; Benedik, J.; Thielmann, M.; Jakob, H. Minimal access versus conventional aortic valve replacement: A meta-analysis of propensity-matched studies†. Interact. Cardiovasc. Thorac. Surg. 2017, 25, 624–632. [CrossRef]
3. Shehada, S.-E.; Öztürk, Ö.; Wottke, M.; Lange, R. Propensity score analysis of outcomes following minimal access versus conventional aortic valve replacement. Eur. J. Cardio-Thoracic Surg. 2015, 49, 464–470. [CrossRef]
4. Mack, M.J.; Leon, M.B.; Thourani, V.H.; Makkar, R.; Kodali, S.K.; Russo, M.; Kapadia, S.R.; Malaisrie, S.C.; Cohen, D.J.; Pibarot, P.; et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N. Engl. J. Med. 2019, 380, 1695–1705. [CrossRef]
5. Popma, J.J.; Deeb, G.M.; Yakubov, S.J.; Muntaz, M.; Gada, H.; O’Hair, D.; Bajwa, T.; Heiser, J.C.; Merhi, W.; Kleiman, N.S.; et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N. Engl. J. Med. 2019, 380, 1706–1715. [CrossRef]
6. Shehada, S.E.; Wendt, D.; Peters, D.; Mourad, F.; Marx, P.; Thielmann, M.; El Gabry, M. Infections after transcatheter versus surgical aortic valve replacement: Mid-term results of 200 consecutive patients. J. Thorac. Dis. 2018, 10, 4342–4352. [CrossRef]
7. Wendt, D.; Shehada, S.-E.; König, L.; Kahlert, P.; Frey, U.; Mourad, F.; Jakob, H.; Thielmann, M.; El Gabry, M. Modified implantation height of the Sapien3™ transcatheter heart valve. Minim. Invasive Ther. Allied Technol. 2019, 29, 70–77. [CrossRef]
8. Haddad, A.; Szalai, C.; van Brakel, L.; Elhmidi, Y.; Arends, S.; Rabis, M.; Pop, A.; Ruhparwar, A.; Brenner, T.; Shehada, S.-E. Fast-track anesthesia in lateral mini-thoracotomy for transapical transcatheter valve implantation. J. Thorac. Dis. 2021, 13, 4853–4863. [CrossRef]
9. Barreto-Filho, J.A.; Wang, Y.; Dodson, J.A.; Desai, M.M.; Sugeng, L.; Geirsson, A.; Krumholz, H.M. Trends in Aortic Valve Replacement for Elderly Patients in the United States, 1999–2011. JAMA 2013, 310, 2078–2084. [CrossRef]
10. Gleason, T.G.; Readon, M.J.; Popma, J.J.; Deeb, G.M.; Yakubov, S.J.; Lee, J.S.; Kleiman, N.S.; Chetcuti, S.; Herrmiller, J.B.; Heiser, J.; et al. 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients. J. Am. Coll. Cardiol. 2018, 72, 2687–2696. [CrossRef]
11. Makkar, R.R.; Thourani, V.H.; Mack, M.J.; Kodali, S.K.; Kapadia, S.; Webb, J.G.; Yoon, S.-H.; Trento, A.; Svensson, L.G.; Herrmann, H.C.; et al. Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. N. Engl. J. Med. 2020, 382, 799–809. [CrossRef]

12. Barili, F.; Freemantle, N.; Pilozzi Casado, A.; Rinaldi, M.; Folliguet, T.; Musumeci, F.; Parolari, A. Mortality in trials on transcatheter aortic valve implantation versus surgical aortic valve replacement: A pooled me-to-analysis of Kaplan-Meier-derived individual patient data. Eur. J. Cardiothorac. Surg. 2020, 58, 221–229. [CrossRef] [PubMed]

13. Ashikhmina, E.A.; Schaff, H.V.; Dearani, J.A.; Sundt, T.M., III; Suri, R.M.; Park, S.J.; Daly, R.C. Aortic valve replacement in the elderly: Determinants of late outcome. Circulation 2011, 124, 1070–1078. [CrossRef]

14. Rodriguez-Gabella, T.; Vosits, P.; Dagenais, F.; Mohammadi, S.; Ferron, J.; Dumont, E.; Puri, R.; Asmarats, L.; Côté, M.; Bergeron, S.; et al. Long-Term Outcomes Following Surgical Aortic Bioprosthesis Implantation. J. Am. Coll. Cardiol. 2018, 71, 1401–1412. [CrossRef] [PubMed]

15. Gaudino, M.; Anselmi, A.; Morelli, M.; Pragliola, C.; Tsiopoulos, V.; Gliica, F.; Possati, G. Aortic expansion rate in patients with dilated post-stenotic ascending aorta submitted only to aortic valve replacement-long-term follow-up. J. Am. Coll. Cardiol. 2011, 58, 581–584. [CrossRef]

16. Yoshitani, H.; Isotani, A.; Song, J.-K.; Shirai, S.; Umeda, H.; Jang, J.Y.; Onoue, T.; Toki, M.; Sun, B.-J.; Kim, D.-H.; et al. Surgical as Opposed to Transcatheter Aortic Valve Replacement Improves Basal Intraventricular Septal Hypertrophy. Circ. J. 2018, 82, 2887–2895. [CrossRef] [PubMed]

17. Rocha, R.V.; Manlihot, C.; Feindel, C.M.; Yau, T.M.; Mueller, B.; David, T.E.; Ouzounian, M. Surgical Remodeling of the Aortic Root Does Not Increase the Operative Risk of Aortic Valve Replacement. Circulationa 2018, 137, 1585–1594. [CrossRef]

18. Di Tommaso, L.; Stassano, P.; Mannacio, V.; Russolillo, V.; Monaco, M.; Pinna, G.; Vosa, C. Asymmetric septal hypertrophy in patients with severe aortic stenosis: The usefulness of associated septal myectomy. J. Thorac. Cardiovasc. Surg. 2013, 145, 171–175. [CrossRef]

19. Camm, C.F.; Nagendran, M.; Xiu, P.Y.; Maruthappu, M. How effective is cryoablation for atrial fibrillation during concomitant cardiac surgery? Interact. Cardiovasc. Thorac. Surg. 2011, 13, 410–414. [CrossRef]

20. Duncan, A.I.; Lowe, B.S.; Garcia, M.J.; Xu, M.; Gillinov, A.M.; Mihaljevic, T.; Koch, C.G. Influence of Concentric Left Ventricular Remodeling on Early Mortality After Aortic Valve Replacement. Ann. Thorac. Surg. 2008, 85, 2030–2039. [CrossRef]

21. Heg, D.; Khattab, A.A.; Meier, B.; Huber, C.; Windecker, S.; Pilgrim, T.; Nietlispach, F.; Jüni, P.; Glökle, S.; Stortecky, S.; et al. Atrial fibrillation and aortic stenosis: Impact on clinical outcomes among patients undergoing transcatheter aortic valve implantation. Circ. Cardiovasc. Inter. 2013, 6, 77–84. [CrossRef]

22. Lancellotti, P.; Magne, J.; Dulgheru, R.; Clavel, M.-A.; Donal, E.; Vannan, M.A.; Chambers, J.; Rosenhek, R.; Habib, G.; Lloyd, G.; et al. Outcomes of Patients With Asymptomatic Aortic Stenosis Followed Up in Heart Valve Clinics. JAMA Cardiol. 2018, 3, 1060–1068. [CrossRef]

23. Fallon, J.M.; DeSimone, J.P.; Brennan, J.M.; O’Brien, S.; Thibault, D.P.; DiScipio, A.W.; Pibarot, P.; Jacobs, J.P.; Malenka, D.J. The Incidence and Consequence of Prosthesis-Patient Mismatch After Surgical Aortic Valve Replacement. Ann. Thorac. Surg. 2018, 106, 14–22. [CrossRef] [PubMed]

24. Kume, Y.; Fujita, T.; Fukushima, S.; Hata, H.; Shimahara, Y.; Matsumoto, Y.; Yamashita, K.; Kobayashi, J. Reducing Prosthesis-Patient Mismatch With Edwards Magna Prosthesis for Aortic Valve Replacement. Circ. J. 2017, 81, 468–475. [CrossRef]

25. Ghoneim, A.; Bouhout, I.; Demers, P.; Mazine, A.; Francispilli, M.; El-Hamamsy, I.; Carrier, M.; Lamarche, Y.; Bouchard, D. Management of small aortic annulus in the era of sutureless valves: A comparative study among different biological options. J. Thorac. Cardiovasc. Surg. 2016, 152, 1019–1028. [CrossRef] [PubMed]

26. Theron, A.; Gariboldi, V.; Grisoli, D.; Jaussaud, N.; Morera, P.; Lapier, D.; Leroux, S.; Amanatiou, C.; Guidon, C.; Riberi, A.; et al. Rapid Deployment of Aortic Bioprosthesis in Elderly Patients With Small Aortic Annulus. Ann. Thorac. Surg. 2016, 101, 1434–1441. [CrossRef] [PubMed]

27. Erbel, R.; Aboyans, V.; Boileau, C.; Bossone, E.; Bartolomeo, R.D.; Kravchenko, I. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic dis-eases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the Euro-pean Society of Cardiology (ESC). Eur. Heart J. 2014, 35, 2873–2926.

28. Yasuda, H.; Nakatani, S.; Stugaard, M.; Tsujiita-Kuroda, Y.; Bando, K.; Kobayashi, J.; Yamagishi, M.; Kitakaze, M.; Kitamura, S.; Miyatake, K. Failure to Prevent Progressive Dilation of Ascending Aorta by Aortic Valve Replacement in Patients With Bicuspid Aortic Valve: Comparison With Tricuspid Aortic Valve. Circ. 2003, 108, II291-4. [CrossRef]

29. Girdauskas, E.; Rouman, M.; Dish, K.; Dubsaff, G.; Fey, B.; Misfeld, M.; Kuntze, T. The fate of mild-to-moderate proximal aortic dilatation after isolated aortic valve replacement for bicuspid aortic valve stenosis: A magnetic resonance imaging follow-up study. J. Cardiothorac. Surg. 2016, 49, e80-6; discussion e86-7. [CrossRef]

30. Ancona, M.B.; Moroni, F.; Chieffo, A.; Spangaro, A.; Federico, F.; Ferri, L.A.; Bellini, B.; Carlino, M.; Romano, V.; Palmisano, A.; et al. Impact of Ascending Aorta Dilation on Mid-Term Outcome After Transcatheter Aortic Valve Implantation. J. Invasive Cardiol. 2019, 31, 278–281.

31. Anselmi, A.; Ruggieri, V.G.; Lelong, B.; Flecher, E.; Corbineau, H.; Langanay, T.; Verhoye, J.-P.; Leguerrier, A. Mid-term durability of the Trifecta bioprosthesis for aortic valve replacement. J. Thorac. Cardiovasc. Surg. 2017, 153, 21–28.e1. [CrossRef] [PubMed]
32. Forcillo, J.; Pellerin, M.; Perrault, L.P.; Cartier, R.; Bouchard, D.; Demers, P.; Carrier, M. Carpentier-Edwards Pericardial Valve in the Aortic Position: 25-Years Experience. *Ann. Thorac. Surg.* 2013, 96, 486–493. [CrossRef] [PubMed]

33. Shan, L.; Saxena, A.; McMahon, R.; Wilson, A.; Newcomb, A. A systematic review on the quality of life benefits after aortic valve replacement in the elderly. *J. Thorac. Cardiovasc. Surg.* 2013, 145, 1173–1189. [CrossRef] [PubMed]